QNCX Latest Press Releases

-- May 18, 2026 --

UPDATE - Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD Globe Newswire 10:21 AM

Quince Announces Acquisition of Orphai and up to $187 Million Private Placement to Advance Pulmonary Pipeline Globe Newswire 9:26 AM

Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD Globe Newswire 9:26 AM

-- March 30, 2026 --

Quince Therapeutics Settles Approximately $16.4 Million of Debt Business Wire 8:30 AM

-- February 9, 2026 --

Quince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Alternatives Business Wire 4:05 PM

-- January 29, 2026 --

Quince Therapeutics Announces Topline Results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-Telangiectasia Business Wire 3:10 PM

-- January 28, 2026 --

Quince Therapeutics Presents Safety Data from Long-Term eDSP Treatment in Children with Ataxia-Telangiectasia at British Paediatric Neurology Association Annual Meeting Business Wire 4:05 PM

Market Data Delayed 15 Minutes

Questions? Feedback?Olark live chat software